BACKGROUND: Human umbilical cord blood (HUCB) is a possible alternative to bone marrow (BM) and mobilized peripheral blood (PB) for transplantation of hematopoietic progenitors. The aim of this study was to evaluate the phenotypic profile of CD34+ progenitors present in HUCB. MATERIALS AND METHODS: A flow cytometric analysis was performed on 20 HUCB samples, using a large panel of monoclonal antibodies recognizing different lineage or activation antigens, in double labeling with CD34. RESULTS: A toal of 13,897 +/- 2,529 cells/microL, 0.84 +/- 0.83% of which were CD34+, was found. The large majority of CD34+ cells were committed toward initial myeloid differentiation (CD33+, CD13+) and expressed the transferrin receptor (CD71). A substantial proportion of these cells (about 40%) co-expressed CD45RA and CD117, while a very small number displayed markers of advanced myeloid commitment, such as CD14, CD15 and CD41 (less than 2%), or those of lymphoid differentiation: CD2, CD5, CD7, CD10 and CD19 (less than 6%). About 11% of HUCB CD34+ cells were primitive progenitors, as suggested by the absence of HLA-DR and CD38 on their surface. CONCLUSIONS: As previously observed in BM and mobilized PB, the phenotype of HUCB CD34+ cells is quite heterogeneous. In particular, HUCB contains subpopulations of both early and committed hematopoietic progenitors which may represent a valid source for transplantation.
BACKGROUND:Human umbilical cord blood (HUCB) is a possible alternative to bone marrow (BM) and mobilized peripheral blood (PB) for transplantation of hematopoietic progenitors. The aim of this study was to evaluate the phenotypic profile of CD34+ progenitors present in HUCB. MATERIALS AND METHODS: A flow cytometric analysis was performed on 20 HUCB samples, using a large panel of monoclonal antibodies recognizing different lineage or activation antigens, in double labeling with CD34. RESULTS: A toal of 13,897 +/- 2,529 cells/microL, 0.84 +/- 0.83% of which were CD34+, was found. The large majority of CD34+ cells were committed toward initial myeloid differentiation (CD33+, CD13+) and expressed the transferrin receptor (CD71). A substantial proportion of these cells (about 40%) co-expressed CD45RA and CD117, while a very small number displayed markers of advanced myeloid commitment, such as CD14, CD15 and CD41 (less than 2%), or those of lymphoid differentiation: CD2, CD5, CD7, CD10 and CD19 (less than 6%). About 11% of HUCB CD34+ cells were primitive progenitors, as suggested by the absence of HLA-DR and CD38 on their surface. CONCLUSIONS: As previously observed in BM and mobilized PB, the phenotype of HUCB CD34+ cells is quite heterogeneous. In particular, HUCB contains subpopulations of both early and committed hematopoietic progenitors which may represent a valid source for transplantation.
Authors: Ning Chen; Siddharth Kamath; Jennifer Newcomb; Jennifer Hudson; Svitlana Garbuzova-Davis; Paula Bickford; Cyndy Davis-Sanberg; Paul Sanberg; Tanja Zigova; Alison Willing Journal: J Neural Eng Date: 2007-04-04 Impact factor: 5.379
Authors: M Mao; G Fu; J S Wu; Q H Zhang; J Zhou; L X Kan; Q H Huang; K L He; B W Gu; Z G Han; Y Shen; J Gu; Y P Yu; S H Xu; Y X Wang; S J Chen; Z Chen Journal: Proc Natl Acad Sci U S A Date: 1998-07-07 Impact factor: 11.205
Authors: Ryan J Ashley; Hongxia Yan; Nan Wang; John Hale; Brian M Dulmovits; Julien Papoin; Meagan E Olive; Namrata D Udeshi; Steven A Carr; Adrianna Vlachos; Jeffrey M Lipton; Lydie Da Costa; Christopher Hillyer; Sandrina Kinet; Naomi Taylor; Narla Mohandas; Anupama Narla; Lionel Blanc Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808
Authors: Fernando de Sá Silva; Paula Nascimento Almeida; João Vitor Paes Rettore; Claudinéia Pereira Maranduba; Camila Maurmann de Souza; Gustavo Torres de Souza; Rafaella de Souza Salomão Zanette; Sueli Patricia Harumi Miyagi; Marcelo de Oliveira Santos; Márcia Martins Marques; Carlos Magno da Costa Maranduba Journal: J Biomed Biotechnol Date: 2012-11-20